Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Saudi Arabia: simulation study

References

• Abraham I, Sun D, Bagalagel A, et al. Biosimilars in 3D: definition, development and differentiation. Bioengineered. 2013;4(4):203–206.
   PubMed Web of Science ®Google Scholar
• Lybecker KM. The biologics revolution in the production of drugs [internet]. Intellect Prop Rights Promot Biol Med Devices Trade Pharm. 2016; [cited 2022 Apr 9]. p. 9. Available from: https://terzadecade.it/download/cellule_tempo_immortalita_-_quattro_storie_di_colture/Intellectual-Property-Rights-and-the-Promotion-of-Biologics-Medical-Devices-and-Trade-in-Pharmaceuticals.pdf#page=13
   Google Scholar
• Khan MA, Aseeri MA, Alshamrani MA, et al. Emerging role of biosimilars in oncology-hematology in Saudi Arabia: a practical perspective. Glob J Qual Saf Healthc. 2020;3(1):22–29.
   PubMedGoogle Scholar
• Ventola CL. Evaluation of biosimilars for formulary inclusion: factors for consideration by P&T committees. P T. 2015;40(10):680–689.
   PubMedGoogle Scholar
• Bellinvia S, Cummings JRF, Ardern-Jones MR, et al. Adalimumab biosimilars in Europe: an overview of the clinical evidence. BioDrugs. 2019;33(3):241–253.
   PubMed Web of Science ®Google Scholar
• Gherghescu I, Delgado-Charro MB. The biosimilar landscape: an overview of regulatory approvals by the EMA and FDA. Pharmaceutics. 2020;13(1):48.
   PubMed Web of Science ®Google Scholar
• Patel D, Gillis C, Naggar J, et al. The rise of biosimilars: how they got here and where they are going. Metabolism. 2017;75:45–53.
   PubMed Web of Science ®Google Scholar
• Moore TJ, Mouslim MC, Blunt JL, et al. Assessment of availability, clinical testing, and us food and drug administration review of biosimilar biologic products. JAMA Intern Med. 2021;181(1):52–60.
   PubMed Web of Science ®Google Scholar
• Wilsdon T, Pistollato M, Ross-Stewart K, et al. Biosimilars: a global roadmap for policy sustainability. https://udibi.com.mx/wp-content/uploads/2022/07/Biosimilars-A-global-roadmap-for-policy-sustainability-16June2022.pdf.
   Google Scholar
• Weycker D, Hackett J, Edelsberg JS, et al. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother. 2006;40(3):402–407.
   PubMed Web of Science ®Google Scholar
• Rastogi S, Kalaiselvan V, Ali S, et al. Efficacy and safety of filgrastim and its biosimilars to prevent febrile neutropenia in cancer patients: a prospective study and meta-analysis. Biology (Basel). 2021;10:1069.
   PubMedGoogle Scholar
• Aapro M, Cornes P, Abraham I. Comparative cost-efficiency across the european G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. J Oncol Pharm Pract. 2012;18(2):171–179.
   PubMedGoogle Scholar
• Alrawashdh N, McBride A, Alkhatib N, et al. Meta-analysis of same-day pegfilgrastim administration stratified by myelotoxic febrile neutropenia risk and tumor type. J Adv Pract Oncol. 2022;13:796–810.
   PubMedGoogle Scholar
• Gascón P, Aapro M, Ludwig H, et al. Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study). Support Care Cancer. 2016;24(2):911–925.
   PubMed Web of Science ®Google Scholar
• Aapro M, Ludwig H, Bokemeyer C, et al. Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study). Ann Oncol. 2016;27(11):2039–2045.
   PubMed Web of Science ®Google Scholar
• Sun D, Andayani TM, Altyar A, et al. Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation study. Clin Ther. 2015;37(4):842–857.
   PubMed Web of Science ®Google Scholar
• Aapro M, Cornes P, Sun D, et al. Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer. Ther Adv Med Oncol. 2012;4(3):95–105.
   PubMed Web of Science ®Google Scholar
• Abraham I, Han L, Sun D, et al. Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries. Futur Oncol. 2014;10(9):1599–1609.
   PubMed Web of Science ®Google Scholar
• McBride A, Campbell K, Bikkina M, et al. Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. J Med Econ. 2017;20(10):1083–1093.
   PubMed Web of Science ®Google Scholar
• McBride A, Wang W, Campbell K, et al. Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastim. J Med Econ. 2020;23(8):856–863.
   PubMed Web of Science ®Google Scholar
• MacDonald K, McBride A, Alrawashdh N, et al. Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv. J Med Econ. 2020;23(12):1466–1476.
   PubMed Web of Science ®Google Scholar
• McBride A, MacDonald K, Fuentes-Alburo A, et al. Conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb: cost-efficiency analysis and budget-neutral expanded access to prophylaxis and treatment. J Med Econ. 2021;24(1):598–606.
   PubMed Web of Science ®Google Scholar
• McBride A, MacDonald K, Fuentes-Alburo A, et al. Cost-efficiency and expanded access modeling of conversion to biosimilar trastuzumab-dkst with or without pertuzumab in metastatic breast cancer. J Med Econ. 2021;24:743–756.
   PubMed Web of Science ®Google Scholar
• McBride A, Balu S, Campbell K, et al. Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz. Future Oncol. 2017;13(25):2285–2295.
   PubMed Web of Science ®Google Scholar
• Aljedai AH, Alhomaidan AM, Trifirò G, et al. First GCC stakeholder meeting on approval process, interchangeability/substitution and safety of biosimilars 2017–report. Generics Biosimilars Initiat J (GaBI Journal). 2018;7:158–163.
   Google Scholar
• AlRuthia Y, Bahari OH, Alghnam S, et al. Real-world impact of switching from insulin glargine (lantus(®) to basaglar(®) and potential cost saving in a large public healthcare system in Saudi Arabia. Front Public Health. 2022;10:852721.
   PubMed Web of Science ®Google Scholar
• Nassir R, Esheba G. Implementation of next-generation sequencing in Saudi Arabia for HER2-positive breast cancer. Saudi J Biol Sci. 2022;29(3):1808–1812.
   PubMed Web of Science ®Google Scholar
• Albeshan SM, Alashban YI. Incidence trends of breast cancer in Saudi Arabia: a joinpoint regression analysis (2004–2016). J King Saud Univ. 2021;33(7):101578.
   Web of Science ®Google Scholar
• Alqahtani WS, Almufareh NA, Domiaty DM, et al. Epidemiology of cancer in Saudi Arabia thru 2010–2019: a systematic review with constrained meta-analysis. AIMS Public Health. 2020;7:679.
   PubMedGoogle Scholar
• Peddi PF, Hurvitz SA. Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential. Ther Adv Med Oncol. 2014;6(5):202–209.
   PubMed Web of Science ®Google Scholar
• Von Minckwitz G, Huang C-S, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617–628.
   PubMed Web of Science ®Google Scholar
• GLOBOCAN 2020. Saudi Arabia Source: globocan incidence, mortality and prevalence by cancer site. 2021. [cited 2022 Aug 4]; Available from: https://gco.iarc.fr/today/data/factsheets/populations/682-saudi-arabia-fact-sheets.pdf.
   Google Scholar
• MNGHA Drug and Pharmacoeconomic Center. GCSF CIF Prices in KSA. Riyadh; 2022.
   Google Scholar
• 1 SAR to USD - Saudi Arabian Riyals to US Dollars Exchange Rate [Internet]. [cited 2022 Jul 2]. Available from: https://www.xe.com/currencyconverter/convert/?Amount=1&From=SAR&To=USD.
   Google Scholar
• Waller CF. Critical appraisal of biosimilar filgrastim (NivestimTM) for febrile and chemotherapy-induced neutropenia. BS. 2012;2:1–11.
   Google Scholar
• Gascón P, Fuhr U, Sörgel F, et al. Development of a new G-CSF product based on biosimilarity assessment. Ann Oncol. 2010;21(7):1419–1429.
   PubMed Web of Science ®Google Scholar
• Gascón P, Tesch H, Verpoort K, et al. Clinical experience with Zarzio® in Europe: what have we learned? Support Care Cancer. 2013;21(10):2925–2932.
   PubMed Web of Science ®Google Scholar
• Tharmarajah S, Abdulaziz M, Bagalagel A, et al. Clinical efficacy and safety of Zarzio®(EP2006), a biosimilar recombinant human granulocyte colony-stimulating factor. Biosimilars. 2014;4:1.
   Google Scholar
• Abraham I, Tharmarajah S, MacDonald K. Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors. Expert Opin Drug Saf. 2013;12(2):235–246.
   PubMed Web of Science ®Google Scholar
• Alghamdi A, Balkhi B, Alqahtani S, et al. The economic burden associated with the management of different stages of breast cancer: a retrospective cost of illness analysis in Saudi Arabia. Healthcare (Basel, Switzerland). 2021;9(7):907.
   PubMedGoogle Scholar
• Saudi Health Council. Cancer incidence report [Internet] 2017. Available from: https://nhic.gov.sa/eServices/Documents/2017.pdf
   Google Scholar
• Bassil N, Sasmaz S, El Sayah M, et al. Realizing biosimilar potential in the Middle East & Africa [Internet]. IQVIA. 2020. p. 1–28. Available from: https://www.iqvia.com/-/media/iqvia/pdfs/mea/white-paper/biosimilar_iqvia-whitepaper_final.pdf.
   Google Scholar
• Ismail S, Abu Esba L, Khan M, et al. An institutional guide for formulary decisions of biosimilars. Hosp Pharm. 2023;58(1):38–48. Available from:
   PubMed Web of Science ®Google Scholar